Pramipexole dihydrochloride monohydrate is an activator of D2DR, D3DR and D4DR. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.
White or almost white, crystalline powder.
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD) and a antidepressant. It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement)
ChEBI: A hydrate that is the monohydrate of the dihydrochloride salt of pramiprexole.
Mirapex (Boehringer Ingelheim).
Pramipexole Dihydrochloride is a non-ergot dopamine agonist widely used for the treatment of early and advanced Parkinson′s disease (PD). It is also used to treat restless legs syndrome.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Parkinson’s disease
Symptomatic treatment of restless legs
Dizziness, lightheadedness, or fainting, especially when standing up suddenly from a sitting/lying position.
drowsiness.
nausea.
seeing, hearing, or feeling things that are not there.
trouble sleeping.
twitching, twisting, or other unusual body movements.
unusual tiredness or weakness.
Potentially hazardous interactions with other drugs
Avoid concomitant use with antipsychotics.
Pramipexole undergoes <10% metabolism to inactive
metabolites.
More than 90% of a dose is excreted via renal tubular
secretion unchanged into the urine.
